The U.S. Food and Drug Administration (FDA) approved a supplemental application for Opdivo (nivolumab) on February 15, 2023. This approval pertains to an efficacy supplement, indicating an update or expansion related to the drug's effectiveness.
Background
Nivolumab, marketed as Opdivo, is an established therapeutic agent. This supplemental approval by the FDA specifically addresses an efficacy update for the drug, as indicated by the application details. The sponsor for Opdivo is Bristol Myers Squibb.
What this means
The FDA's approval of this supplemental application for Opdivo (nivolumab) signifies an update or expansion of the drug's demonstrated efficacy. While the specific details of the new or updated indication are not provided in the summary, such approvals typically allow for broader use, updated dosing, or an expanded patient population for which the drug has shown benefit. This regulatory action reinforces the drug's profile as an effective treatment option in its approved therapeutic areas.
Source
The information regarding this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA). The approval for BLA 125554 S-117, an efficacy supplement for Opdivo (nivolumab), was granted on February 15, 2023, and is publicly accessible on accessdata.fda.gov.